Progesterone capsules are suitable for the treatment of various hormone related diseases, and special attention should be paid to dosage adjustment and monitoring in different populations. The following is a detailed explanation of the specific applicable population and special precautions.

Applicable Population

1. Patients with gynecological diseases

Used for treating amenorrhea, functional uterine bleeding, etc., the dosage should be adjusted according to the thickness of the endometrium, usually 200-300mg/day.

2. Assisted reproductive technology

For luteal support during IVF cycles, the recommended dosage is 400-600mg/day, and vaginal administration can reduce systemic side effects.

3. Pregnant women with threatened miscarriage

Early pregnancy use requires strict evaluation of indications, with a dose not exceeding 200mg/day and medication not exceeding 12 weeks.

Medication for special populations

1. Pregnancy period

Possible impact on the fetus, it is necessary to confirm the pregnancy status and evaluate the risk benefit ratio before use.

2. Lactation period

Progesterone can enter breast milk, and breastfeeding should be suspended during treatment to avoid affecting infant development.

3. Liver dysfunction

Reduce the dosage by 50% and closely monitor liver function. It is contraindicated for patients with severe liver disease.

4. Renal insufficiency

Mild to moderate doses do not require adjustment, while severe patients should use with caution and monitor changes in renal function.

5. Elderly people

Patients over 65 years old should reduce the starting dose by 25% and pay attention to monitoring cognitive function and thrombus risk.

Precautions

1. Medication monitoring

Regularly check serum progesterone levels, liver function, and endometrial condition, and adjust dosage in a timely manner.

2. Adverse reaction management

When severe dizziness, allergic reactions, or thrombotic symptoms occur, medication should be stopped immediately and medical attention should be sought.

3. Drug interactions

CYP3A4 inducers may reduce drug efficacy, while inhibitors may increase the risk of adverse reactions.